Hormonal contraception: State of the art and future perspectives

Minerva Ginecologica

Volumn 59, Issue 3, 2007, Pages 241-270

  Benagiano, G ^a   Bastianelli, C ^a   Farris, M ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Contraception; Estrogens; Progesterins

Indexed keywords

CONTRACEPTIVE AGENT; ESTROGEN; GESTAGEN; POLYMER; PROGESTERONE RECEPTOR MODULATOR;

AEROSOL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SYNTHESIS; FERTILITY; GEL; HORMONAL CONTRACEPTION; HUMAN; MONOTHERAPY; REVIEW; SEXUAL INTERCOURSE; SUSTAINED DRUG RELEASE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, INTRAVAGINAL; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, SYNTHETIC; DESOGESTREL; DRUG THERAPY, COMBINATION; ESTROGENS; FAMILY PLANNING SERVICES; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTRAUTERINE DEVICES; PROGESTINS; TREATMENT OUTCOME;

EID: 34547639308     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Djerassi C. Progestins in therapy, historical developments. In: Benagiano G, Zulli P, Diczfalusy E editors. New York: Raven Press; 1983. p. 1-13.
2. Rock J, Pincus G, Garcia CR. Effects of certain 19-Nor steroids on reproductive processes in animals. Science 1956;124:890-8.
3. Pincus G, Rock J, Garcia CR. Effectiveness of an oral contraceptive. Science 1959;130:81-5.
4. Djerassi C, Miramontes L, Rosenkranz G. 19-nor-17-ethinylandrosten- 17β-ol-3-one and processes. U.S. Patent No. 2. 1956;744:122.
5. Potts M. Introduction. In: Goldzieher JW, Fotherby K editors. Pharmacology of the Contraceptive Steroids. New York: Raven Press; 1994. p. 1-4.
6. Benagiano G. Male and female reproductive strategies. Edwards symposium. Reprod BioMed Online 2002;4 Suppl 1:72-6.
7. Pornel B, Spielman D. A study of the control of climacteric symptoms in postmenopausal women following sequential regimens of 1 mg 17β-estradiol and trimegestone compared with a regimen containing 1 mg estradiol valerate and norethisterone over a two-year period. Gynecol Endocrinol 2005;21:74-81.
8. Oriowo MA, Landgren B-M, Stentström B, Diczfalusy E. A comparison of the pharmacokinetic profiles of three oestradiol esters. Contraception 1980;21:415-21.
9. Benagiano G, Primiero FM. Cycloprovera. In: Zatuchni GI, Goldsmith A, Shelton JD, Sciarra JJ editors. Long-acting contraceptive delivery systems. PARFR Series on Fertility Regulation. Philadelphia: Harper & Rowe; 1983. p. 523-36.
10. Benagiano G, Primiero FM, Farris M. Clinical profile of contraceptive progestins. Eur J Contracept Reprod Health Care 2004;9:182-93.
11. Carr BR. Uniqueness of oral contraceptive progestins. Contraception 1998;58:23S-7S.
12. Neumann F, Duesterberg B, Laurent H. Development of progestogens. In: Runnebaum B, Rabe T, Kiesel L editors. Female contraception. Berlin, Heidelberg: Springer-Verlag; 1988.
13. Raudrant D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003;63:463-92.
14. Neumann F. The antiandrogen cyproterone acetate: discovery, chemistry, basic pharmacology, clinical use and tool in basic research. Exp Clin Endocrinol 1994;102:1-32.
15. Brennan DM, Kraay RJ. Chlormadinone acetate; a new highly active gestation-supporting agent. Acta Endocrinol (Copenh) 1963;44:367-79.
16. Junchen M. Dienogest: Bindungs-Studien an veschienden Rezeptor und Serumprotein. In: Teichman AT editor. Dienogest - Praklink und Klinik Eines neuen Gestagenes. Berlin: Walter De Gruyter Verlag; 1995. p. 119-33.
17. Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000;5:124-34.
18. Huber HJ, Foidart JM, Wuttke W, Merki-Feld GS, The HS, Gerlinger C et al. Efficacy tolerability of a monophasic oral contraceptive containing ethinyl estradiol and drospirenone. Eur J Contracept Reprod Health Care 2000;5:25-34.
19. Sitruk-Ware R, Small M, Kumar N, Tsong YY, Sundaram K, Jackanicz T. Nestorone: clinical applications for contraception and HRT. Steroids 2003;68:907-13.
20. Johansson ED, Sitruk-Ware R. New delivery systems in contraception: vaginal rings. Am J Obstet Gynecol 2004;190 Suppl 4:S54-9.
21. André G. Actions d'un progestatif dérivé de la 19-nor-progestérone sur la glande mammaire: le nomégestrol acétate. J Gynecol Obstet Biol Reprod 2005;34:69-84.
22. Sartwell PE, Masi AP, Arthes G, Greene GR, Smith HE. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 1969;90:365-80.
23. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J 1986;292:526-32.
24. Rosenberg L, Palmer JR, Sands MI, Grimes D, Bergman U, Daling J et al. Modern oral contraceptives and cardiovascular diseases. Am J Obstet Gynecol 1997;177:707-15.
25. Benagiano G, Primiero FM. Safety of modern oral contraception: the options for women. Hum Reprod Update 1998;5:633-8.
26. Fotherby K, Caldwell ADS. New progestogens in oral contraception. Contraception 1994;49:1-32.
27. Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60μg) and ethinyl estradiol (15μg) on ovarian activity. Fertil Steril 1999;72:115-20.
28. World Health Organization. Selected practice recommendations for contraceptive use. Second edition. Geneva: World Health Organisation; 2005.
29. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999;181:1263-9.
30. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit. FFPRHC Guidance on first prescription of combined oral contraception. J Fam Plann Reprod Health Care 2003;29:209-23.
31. Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. Contraception 1999;59:71-8.
32. Belsey EM, Farley TMM. The analysis of menstrual bleeding pattern: a review. Contraception 1988;38:129-56.
33. WHO, World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
34. EMEA Committee for Proprietary Medicinal Products (CPMP). CPMP Public Assessment Report. Combined oral contraceptives and venous thromboembolism. EMEA/CPMP/ 2201/01. London: EMEA; 2001.
35. Heinemann L, Lewis MA, Spitzer WO, Guggenmoos-Holzmann I, Bruppacher R. Case-control study of oral contraceptives and risk of thromboembolic stroke: results from international study on oral contraceptives and health of young women (transnational). BMJ 1997;315:1502-4.
36. Dunn N, Thorogood M, Faragher B, de Caestecker L, MacDonald TM, McCollum C et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999;318:1579-84.
37. Lewis MA, Heinemann LA, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997;56:129-140.
38. Schwartz SM, Siscovick DS, Longstreth WT Jr, Psaty BM, Beverly RK, Raghunathan TE et al. Use of low-dose oral contraceptives and stroke in young women. Ann Intern Med 1997;127:596-603.
39. Poulter NR, Chang CL, Farley TMM, Marmot MG, Meirik O. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. WHO Collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 1999;354:301-2.
40. Lidegaard O, Kreiner S. Cerebral thrombosis and oral contraceptives: a case-control study. Contraception 1998;57:303-14.
41. Jick SS, Myers MW, Jick H. Risk of idiopathic cerebral haemorrhage in women on oral contraceptives with differing prostagen components. Lancet 1999;354:302-3.
42. Stanford JL. Oral contraceptives and neoplasia of the ovary. Contraception 1991;43:543-56.
43. Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. Contraception 1991;43:557-79.
44. World Health Organization (WHO). Oral Contraceptives and Neoplasia. Technical Report Series No 817. Geneva: WHO; 1992.
45. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives. Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
46. Harlap S, Davies M. The pill and births: The Jerusalem study. NICHD contract Report HD-4-2853. Bethesda, MD: NICHD; 1978.
47. Benagiano G, Goldzieher JW. Effects of contraception on progeny. Rev Perinat Med 1979;3:115-54.
48. World Health Organization (WHO). Improving access to quality care in family planning. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: WHO; 2004.
49. Hampton RM, Short M, Bieber E, Bouchard C, Ayotte N, Shangold G et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho TriCiclen Lo) with the oral contraceptive Fe 1/20. Contraception 2001;63:289-95.
50. Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (desogestrel/ethinyl estradiol) and Ortho Novum 7/7/7 (norethindrone/ethinyl estradiol): a randomised clinical trial. Contraception 2000;61:295-302.
51. Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during post-menopausal replacement therapy. N Engl J Med 1981;304:560-3.
52. Kaunitz AM. Beyond the pill: New data and options in hormonal and intrauterine contraception. Am J Obstet Gynecol 2005;92:998-1004.
53. Hussain A, Ahsan F. The vagina as a route for systemic drug delivery. J Control Release 2005;103:301-13.
54. Diaz S. Contraceptive Vaginal Rings. International Planned Parenthood Federation Medical Bulletin 1999;33:3-4.
55. Upadhyay UD. New Contraceptive Choices. Population Reports. Series M, No.19. Baltimore, MD: Johns Hopkins Bloomberg School of Public Health; 2005.
56. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with a combined contraceptive vaginal ring and oral levonorgestrel/ethinyl estradiol. Am J Obstet Gynecol 2002;186:389-95.
57. Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001;98:799-805.
58. Stewart FH, Kaunitz AM, Laguardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ethinylestradiol: a randomized trial. Obstet Gynecol 2005;105:1389-96.
59. International Planned Parenthood Federation (IPPF). Directory of Hormonal Contraceptives. 2003. Available from: http.//Contraceptive.Ippf.Org.
60. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F editors. Contraceptive technology. 18th ed. New York: Ardentmedia; 2004.
61. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. J Am Med Ass 2001;285:2347-54.
62. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Orthoevra/Evra transdermal system: the analysis of pooled data. Fertil Steril 2002;77 Suppl 2:S13-8.
63. Heger-Mahn D, Warlimont C, Faustmann T, Gerlinger C, Klipping C. Combined ethinyl estradiol/gestodene contraceptive patch: two-center, open label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. Eur J Contracept Reprod Health Care 2004;9:173-81.
64. Newton JR, D'Arcangues C, Hall PE. A review of "once-a month" combined injectable contraceptives. J Obstet Gynecol 1994;4 Suppl 1:S1-S34.
65. Rahimy MH, Ryan KK. Lunelle monthly contraceptive injection, (medroxyprogesterone acetate and estradiol cypionate injectable suspension): assessment of return of ovulation after three monthly injections in surgically sterile women. Contraception 1999;60:189-200.
66. Bahamondes L, Marchi NM, Nakagava HM, de Melo ML, Cristofoletti Mde L, Pellini E, et al. Self-administration with Uniject of the once-a-month injectable contraceptive Cyclofem. Contraception 1997;56:301-4.
67. McCann MF, Potter LS. Progestin-only contraception: a comprehensive review. Contraception 1994; 50(suppl. 1):S1-S198.
68. Landgren BM, Diczfalusy E. Hormonal effects of the 300mg norethisterone (NET) minipill. 1. Daily steroid levels in 43 subjects during a pre-treatment cycle and during the second month of NET administration. Contraception 1980;21:87-113.
69. Viinikka L, Ylikorkala O, Vihko R, Wijnand HP, Booij M, van der Veen F. Metabolism of a new synthetic progestogen ORG 2969, in female volunteers. Investigation into the pharmacokinetics after a single dose. Eur J Clin Pharmacol 1979;15:349-55.
70. Skouby SO. Laboratory and clinical assessment of a new progestational compound desogestrel. Acta Obstet Gynaecol Scand Suppl 1982;111:7-11.
71. Rice C, Killick S, Hickling D, Coelingh-Bennink H. Ovarian activity and vaginal bleeding patterns with a desogestrel-only preparation at three different doses. Hum Reprod 1996;11:737-40.
72. Collaborative Study Group on the Desogestrel-Containing Progestogen-only Pill. A double blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen only pills containing desogestrel 75μg/day or levonorgestrel 30μg/day. Eur J Contracept Reprod Health Care 1998;3:169-78.
73. Rice CF, Killick SR, Dieben T, Coelingh-Bennink H. The effect of desogestrel 75μg and levonorgestrel 30μg on the endometrium and bleeding patterns over one year. Br J Obstet Gynaecol 1998;105 Suppl 17:114-20.
74. Rice CF, Killick SR, Dieben T, Coelingh-Bennink H. A comparison of the inhibition of ovulation, achieved by desogestrel 75μg and levonorgestrel 30μg daily. Hum Reprod 1999;14:982-5.
75. Benagiano G, Primiero FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann NY Acad Sci 2003;997:163-73.
76. Belsey EM and WHO Task Force on Long-acting Systemic Agents for Fertility Regulation. Vaginal bleeding patterns among women using one natural and eight hormonal methods of contraception. Contraception 1988;38:181-206.
77. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75μg/day) or levonorgestrel (30μg/day) on lipid metabolism. Contraception 2000;64:295-9.
78. Kivelä A, Ruuskanen M, Agren U, Dieben T. A doubleblind study comparing the effects of two progestogen-only pills containing either desogestrel (75μg/day) or levonorgestrel (30μg/day) on carbohydrate metabolism and adrenal and thyroid function. Eur J Contracept Reprod Health Care 2001;6:71-7.
79. Winkler UH, Howie H, Buhler K, Korver T, Geurts TB, Coelingh Bennink HJ. A randomized controlled doubleblind study of the effects on hemostasis of two progestogen-only pills containing 75μg desogestrel or 30mu;g levonorgestrel. Contraception 1998;57:385-92.
80. WHO Task Force on Oral Contraceptives. Effects of hormonal contraceptives on breast milk composition and infant growth. Stud Fam Plann 1988;19:361-9.
81. Bjarnadóttir RI, Gottfredsdottir H, Sigurdardottir K, Geirsson RT, Dieben TO. A comparative study on the effects of a progestogen-only pill containing desogestrel and an intrauterine contraceptive device in lactating women. Br J Obstet Gynaecol 2001;108:1174-80.
82. Zanartu J, Rice-Wray E, Goldzieher JW. Fertility control with long-acting injectable steroids. A preliminary report. Obstet Gynecol 1966;28:513-5.
83. Coutinho EM, de Souza JC, Csapo AI. Reversible sterility induced by medroxyprogesterone acetate. Fertil Steril 1968;17:261-6.
84. Benagiano G. Long-acting systemic contraceptives. In: Diczfalusy E editor. Regulation of Human Fertility: Proceedings of a Symposium on Advances in Fertility Regulation, Moscow, 16-19 November 1976. Copenhagen: Scriptor; 1977. p. 323-60.
85. Zanartu J, Onetto E. Long-acting injectable progestogens in human fertility control. In: First International Planned Parenthood Federation, South-East Asia and Oceania Regional Medical and Scientific Congress. Aust NZ J Obstet Gynaecol 1972;Suppl:65-79.
86. Rice-Wray E, Becerra C, Maqueo M. Fertility control with an injectable of a progestogen-estrogen combination. Sixth Pan American Congress of Endocrinology. Excerpta Med Int Congr Series 1966;99:149.
87. Schwallie PC. Experience with Depo-Provera as an injectable contraceptive. J Reprod Med 1974;13:113-7.
88. Schwallie PC, Assenzo JR. Contraceptive use-efficacy study utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973;24:331-9.
89. Benagiano G, Fraser I. The depo-provera debate: commentary on the article "Depo-Provera, a critical analysis". Contraception 1981;24:493-528.
90. Benagiano G, Diczfalusy E, Goldzieher JW, Gray R, Apelo R, Bergstein N et al. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxy-progesterone acetate: 1. Use-effectiveness. Contraception 1977;15: 513-33.
91. Benagiano G, Diczfalusy E, Diethelm P, Gray R, Apelo R, Bergstein N et al. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone oenanthate and medroxy-progesterone acetate. 2. Bleeding patterns and side effects. Contraception 1978;17:395-406.
92. Greydanus D, Dilip E, Patel R, Rimsza M E. Contraception in the adolescent: an update. Pediatrics 2001;107:562-73.
93. Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA et al. Phase III comparison of depomedroxy-progesterone acetate to venlafaxine for managing hot flashes: North central cancer treatment group trial N99C7. J Clin Oncol 2006;24:1409-14.
94. Benagiano G, Gray R, Parker R, Apelo A, de Souza JC, Engel R et al. Multinational comparative clinical evaluation of contraceptive effectiveness of norethisterone oenanthate injected every 60 to 84 days. Seventh Asian Congress of Obstetrics and Gynaecology, 1977, November 20-25, Bangkok.
95. Benagiano G, Fotherby K, Coutinho E, Takker D, Coutinho E, Koetsawang S et al. Return of ovarian function and endometrial morphology in women treated with norethisterone oenanthate: a pilot study. Fertil Steril 1980, 34:456-60.
96. Benagiano G, Primiero FM. Norethindrone enanthate. In: Mishell DR Jr editor. Long-acting steroid contraception. New York: Raven Press; 1983. p. 31-64.
97. Achari K. Effect of norethisterone enanthate (SH 393) on the structure of the endometrium and of the cervical mucus. J Obstet Gynaecol India 1969;19:731-6.
98. Kesseru E, Larranaga A. Mecanismo de accion de los contraceptivos inyectables de deposito. Ginecol Obstet (Peru) 1968;14:339-59.
99. Massai R Diaz S, Jackanicz T, Croxatto HB. Vaginal rings for contraception in lactating women. Steroids 2000;65:703-7.
100. Sitruk-Ware R. Contraceptive development at the Population Council. 2004.
101. Sivin I, Campodonico I, Kiriwat O, Holma P, Diaz S, Wan L et al. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. Hum Reprod 1998;13:3371-8.
102. Croxatto HB, Makarainen N. Pharmacodinamics and efficacy of Implanon. Contraception 1998;58:91S-7S.
103. Devoto L, Kohen P, Barnhart K, Alba F, Pommer R, Retamales I et al. Hormonal profile, endometrial histology and ovarian ultrasound assessment during 1 year of nomegestrol acetate implant (Uniplant). Hum Reprod 1997;12:708-13.
104. Sivin I, Croxatto H, Bahamondes L, Brache V, Alvarez F, Massai R et al. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women. Contraception 2004;69:137-44.
105. Massai MR, Diaz S, Quinteros E, Reyes MV, Herreros C, Zepeda A et al. Contraceptive efficacy and clinical performance of Nestorone implants in postpartum women. Contraception 2001;64:369-76.
106. Carenza L, Ermini M, Pala A, Benagiano G. Effetto dei dispositivi intrauterini liberanti progesterone sull'asse ipotalamo-ipofiso-ovarico nella donna. Patol Clin Ostet Ginec (Rome) 1976;4:109-15.
107. Wan LS, Hsu YC, Ganguly M, Bigelow B. Effects of the Progestasert on the menstrual pattern, ovarian steroid and endometrium. Contraception 1977;16:417-34.
108. Hagenfeldt K, Landgren BM. Contraception by intrauterine release of progesterone - effects on endometrial trace elements enzymes and steroids. J Steroid Biochem 1977;56:895-8.
109. Hagenfeldt K, Landgren BM, Edstrom K, Johannisson E. Biochemical and morphological changes in the human endometrium induced by the progestasert device. Contraception 1977;16:183-97.
110. Ermini M, Carpino F, Petrozza V, Benagiano G. Distribution and effect on the endometrium of progesterone release from a progestasert device. Hum Reprod 1989;4:221-8.
111. Shaw ST, Macaulay LK, Aznar R, Gonzalez-Angulo A, Roy S. Effect of progesterone-releasing intrauterine contraceptive device on endometrial blood vessels: a morphometric study. Am J Obstet Gynecol 1981;141:821-39.
112. Snowden R. The Progestasert and ectopic pregnancy. Br Med J 1977;2:1600-1.
113. Nilsson C-G, Johansson EDB, Luukkainen TA. d-norgestrel-releasing IUD. Contraception 1976;13:503-14.
114. Faculty of Family Planning and Reproductive Health Care. FFPRHC Guidance. The levonorgestel releasing system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 2004;30:99-109.
115. Andersson K, Odlind V, Rybo G. Levonorgestrel releasing and copper releasing (Nova T) IUDs during five years of use: a randomised trial. Contraception 1994;49:56-72.
116. French RS, Cowan FM, Mansour D, Higgins JP, Robinson A, Procter T et al. Levonorgestrel-releasing (20μg/day) intrauterine system (Mirena) compared with other method of reversible contraception. Br J Obstet Gynecol 2000;107:1218-25
117. Luukkainen T, Lahteenmaki PLA, Toivonen J. Levonorgestrel-releasing intrauterine device. Ann Med 1990;22:85-90.
118. Lukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 2000;65:699-702.
119. Irvine GA. Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT et al. Randomised comparative trial of levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynecol 1998;105:592-8.
120. Stewart A Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel releasing intrauterine system in menorrhagia: a systematic review. Br J Obstet Gynecol 2001;108:74-86.
121. Barbosa I, Bakos O, Olsson SE, Odlind V, Johansson ED. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990;42:51-66.
122. Nilsson CG, Lahteemaki PLA, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984;41:52-5.
123. Jonsson B, Landgren B-M, Eneroth P. Effects of various IUDs on the composition of cervical mucus. Contraception 1991;43:447-58.
124. French RS Cowan FM, Mansour DJ, Morris S, Procter T, Hughes D et al. Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraception: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness. Health Technol Assess 2000;4:i-iv, 1-107.
125. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel releasing intrauterine device and Nova T. Contraception 1992;46:575-84.
126. Young E. Spray-on female contraceptive to start trial. New Scientist (Sydney, Australia), 2003, November 27.
127. Batista MC, Cartledge TP, Zellmer AW, Nieman LK, Merriam GR, Loriaux DL. Evidence for a critical role of progesterone in the regulation of the midcycle gonadotrophin surge and ovulation. J Clin Endocrinol Metab 1992;74:565-70.
128. World Health Organization. Levonorgestrel for Emergency Contraception WHO/RHR/Fact Sheet 244. Geneva: WHO; 2005.
129. World Health Organization. Emergency Contraception: a guide for service delivery. WHO/FRH7FPP798.19. Geneva: WHO; 1998.
130. Baird D, Glasier AF. Science, medicine and the future: Contraception. BMJ 1999;319:969-72.
131. Croxatto HB, Salvatierra AM, Fuentealba B, Massai R. Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women. Hum Reprod 1998;13:3297-302.
132. von Hertzen H, Van Look P. Antiprogestins for contraception? In: Carr BR, Spitz IM editors. Progesterone Receptor Antagonists and Selective Progesterone Receptor Modulators (SPRMs). Semin Reprod Med 2005;23:91-100.
133. Gemzell-Danielsson K, van Heusden AM, Killick SR, roxatto HB, Bouchard P, Cameron S et al. Improving cycle control in progestogen-only contraceptive pill users by intermittent treatment with a new antiprogestogen. Hum Reprod 2002;17:2588-93.
134. Cheng L, Zhu H, Wang A, Ren F, Chen J, Glasier A. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum Reprod 2000;15:1969-72.
135. Massai MR, Pavez M, Fuentealba B, Croxatto HB, d'Arcangues C. Effect of intermittent treatment with mifepristone on bleeding patterns in Norplant implant users. Contraception 2004;70:47-54.
136. Yuzpe AA. Post-coital contraception - A pilot study. J Reprod Med 1974;30:12-8.
137. Hoffman KO. Postcoital contraception: Experiences with ethynil estradiol/norgestrel and levonorgestrel only. In: Harrison RF, Bonnar J, Thompson W editors. Proceedings XIth Congr Fertil Steril. Lancaster: MTP Press Ltd; 1984. p. 311-6.
138. World Health Organization. Task Force on Post-Ovulatory Methods for Fertility Regulation. Special Programme for Research Training in Human Reproduction. Post coital contraception with levonorgestrel during the peri-ovulatory phase of the menstrual cycle. Contraception 1997;36:257-86.
139. Task Force on Postovulatory Methods of Fertility Regulation. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Lancet 1998;352:428-33.
140. Benagiano G, Farris M, Bastianelli C. Emergency contraception. In: Genazzani AR, Schenker J, Artini PG, Simoncini T editors. Human Reproduction. Roma: CIC Edizioni Internazionali; 2005. p. 40-47.
141. Aubènv E, Baulieu EE. Activitè contragestive de l'association au RU486 d'une prostaglandine active par voie orale. CR Acad Sci 1991;312:539-45
142. Comparison of three single doses of mifepristone as emergency contraception: a randomized trials. Task Force on Post-Ovulatory Methods for Fertility Regulation Lancet 1999;353:697-702.
143. von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bartfai G et al. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomized trial. Lancet 2000;360:1803-10.
144. von Hertzen H, Piaggio G. Levonorgestrel and mifepristone in emergency contraception. Steroids 2003;68:1107-13.
145. Ashok PW, Stalder C, Wagaarachchi PT, Flett GM, Melvin L, Templeton A. A randomized study comparing a low dose of mifepristone and the Yuzpe regimen for emergency contraception. Br J Obstet Gynaecol 2002;109:553-60.
146. International Medical Advisory Panel, International Planned Parenthood Federation. IMAP statement on emergency contraception. IPPF Med Bull 2004;38:1-3.
147. Croxatto HB, Fuentealba B, Brache V, Salvatierra AM, Alvarez F, Massai R et al. Effects of the Yuzpe regimen, given during the follicular phase on ovarian function. Contraception 2002;65:121-8.
148. Hapangama D, Glasier AF, Baird DT. The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle. Contraception 2001;63:123-9.
149. Landgren BM, Johannisson E, Aedo AR, Kumar A, Shi YE. The effect of levonorgestrel administered in large doses at different stages of the cycles on ovarian function and endometrial morphology. Contraception 1989;39:275-89.
150. Kesseru E, Garmendia F, Westphal N, Parada J. The hormonal peripheral effects of dl-norgestrel in post-coital contraception. Contraception 1974;10:411-24.
151. Swahn ML, Westlund P, Johannisson E, Bygdeman M. Effect of post-coital contraceptive methods on the endometrium and the menstrual cycle. Acta Obstet Gynecol Scand 1996;75:738-44.
152. Croxatto HB, Devoto L, Durand M, Ezcurra E, Larrea F, Nagle C et al. Mechanism of action of hormonal preparations used for emergency contraception: a review of the literature. Contraception 2001;63:111-21.
153. Marions L, Hultenby K, Lindell I, Sun X, Stabi B, Gemzell Danielsson K. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol 2002;100:65-71.